Axon degeneration is a critical pathological feature of many neurodegenerative diseases. Misregulation of local axonal ion homeostasis has been recognized as an important yet understudied mechanism for axon degeneration. Here we report a chemically induced, recessive mouse mutation, vacillator ( vac), which causes ataxia and concomitant axon degeneration of cerebellar Purkinje cells. By positional cloning, we identified vac as a point mutation in the calcineurin-like EF hand protein 1 ( Chp1) gene that resulted in the production of mutant Chp1 isoforms with an amino acid substitution in a functional EF-hand domain or a truncation of this motif by aberrant splicing and significantly reduced protein levels. Chp1 has been previously shown to interact with the sodium hydrogen exchanger 1 ( NHE1), a major regulator of intracellular pH. We demonstrated that Chp1 assists in the full glycosylation of NHE1 that is necessary for the membrane localization of this transporter and that truncated isoforms of Chp1 were defective in stimulating NHE1 biosynthetic maturation. Consistent with this, membrane localization of NHE1 at axon terminals was greatly reduced in Chp1-deficient Purkinje cells before axon degeneration. Furthermore, genetic ablation of Nhe1 also resulted in Purkinje cell axon degeneration, pinpointing the functional convergence of the two proteins. Our findings clearly demonstrate that the polarized presynaptic localization of NHE/CHP1 is an important feature of neuronal axons and that selective disruption of NHE1-mediated proton homeostasis in axons can lead to degeneration, suggesting that local regulation of pH is pivotal for axon survival.
gene, which causes an amino acid substitution and abnormal splicing, resulting in reduced CHPI protein levels. Moreover, whereas wild-type CHPI promotes full glycosylation and thus plasma membrane localization of NHE1, two of the mutant isoforms lack this activity. As a result, NHE1 levels were reduced at a subset of presynaptic terminals in the Chp1 vac/vac brain, including those of Purkinje cells. Conversely, ablation of Nhe1 caused a reduction of CHPI in these structures, demonstrating the interdependence of NHE1 and CHPI in membrane localization. Last, we demonstrated that Purkinje cell axon degeneration also occurs in Nhe1 mutant mice, confirming the functional coupling of NHE1 and CHPI in regulating local pH at axon terminals.

Materials and Methods

Immunohistochemistry. Anesthetized mice were fixed by transcardial perfusion with 4% paraformaldehyde in PBS. Brains were dissected and postfixed in 4% paraformaldehyde for 2 h before paraffin embedding. For colorimetric calbindin D-28 staining, Bouin’s fixative was used for perfusion and postfixation. For immunofluorescence with anti-CBP antibodies, antigen retrieval was performed by microwave heating in 0.01 M sodium citrate buffer, pH 6.0. For immunostaining with anti-CHPI antibodies, antigen retrieval was performed by incubating sections in a 1:100 dilution of 0.25% trypsin-EDTA (Invitrogen) in PBS at 37°C for 6 min. After antigen retrieval, sections were blocked with 4% goat serum in PBST (0.02% Triton in PBS), followed by 4°C overnight incubation with primary antibodies. Fluorescent detection was performed with Alexa Fluor-488- and Alexa Fluor-555-conjugated secondary antibodies (1:200; Invitrogen). For 3,3'-diaminobenzidine detection of bound calbindin D-28 antibodies, sections were incubated with biotin-conjugated anti-rabbit IgG antibody (1:100; Sigma) and ExtrAvidin-peroxidase (1:50; Sigma). For all immunohistochemical analyses, at least three mice of each genotype and age were used. Primary antibodies were as follows: rabbit anti-CHPI (affinity purified, custom-made against recombinant full-length mouse CHPI protein; Proteintech), rabbit anti-calbindin D-28 (1:500; Swant), mouse anti-calbindin D-28 (1:500; Sigma), mouse anti-glutamate decarboxylase (anti-GAD, 1:300; BML), mouse anti-PSD95 (1:200; clone 24/L8; University of California–Davis/National Institutes of Health NeuroMab Facility), mouse anti-NHE1 (1:100; BD Biosciences), mouse anti-neurofilament medium chain (NFM, 1:300; Invitrogen), and rabbit anti-PKCγ (1:200; Abcam).

TEM. Anesthetized mice were fixed by transcardial perfusion with PBS, followed by perfusion with 2% paraformaldehyde and 2% glutaraldehyde in cacodylate buffer, pH 7.2. After overnight postfixation in the same fixative, brains were dissected and processed for transmission electron microscopy using standard procedures (Bechtold, 2000). TEM images were collected on a Jeol 1230 microscope.

Mouse strains. The vac mutation was identified in an N-ethyl-N-nitrosourea (ENU)-induced mutagenesis screen at The Jackson Laboratory (Handel et al., 2006). ENU-injected C57BL/6J male mice were crossed to C3H/HeFeJ male mice to produce G1 founder males. Each G1 founder was crossed to C3H/HeFemale mice to obtain G2 female mice that were potential mutation carriers. These G2 female mice were backcrossed to the G1 founder to generate homozygous mutant offspring. The vac mutant line was maintained by continued backcrossing of heterozygotes onto C57BL/6J mice for 13 generations (N13). All analyses were performed using N9–N13 B6.Cg-Chpi vac mice unless otherwise specified. The B6.SJL-Slea1v congenic strain was described previously (Cox et al., 1997). Three to five mice (including both males and females) of each genotype were analyzed for each data point. The animal care and use committee of The Jackson Laboratory approved all animal protocols.

Chpi vac mice were identified by allele-specific PCR, with forward primers chpex1F (5’-AGGCGCTGACCAAGATGGTG-3’) or chpmtF (5’-GGAGCCTGACCAAGATGGTG-3’) to detect the wild-type or mutant Chpi allele, respectively. Each forward primer was multiplexed with two common primers: chpmutF (5’-CTCTAGAACCTTGCTTCTGTG-3’) and chpintrF (5’-AACCCTTCTCTCCTATGCAG-3’) at a 3:14 ratio. Two amplicons were produced for each PCR: a 432 bp product from the allele-specific forward primer and chpmtF and a 527 bp control product from chpmutF and chpintrF.

To generate RP23–2222L3 transgenic lines, the C57BL/6J-derived BAC RP23–2222L3 was injected into the pronuclei of C57BL/6J zygotes. Three founders were identified by PCR with the primer pair Bac7TF, 5’-GCTATAAACCTCAGACATG-3’ and Bac237TR, 5’-TGAATCATAGGGCTTGGACAC-3’, which recognize the BAC backbone sequence and the 17’ end of the inserted genomic fragment, respectively. Founders were crossed to C57BL/6J wild-type (Chpi wild-type) female mice and only line Tg21 displayed successful germline transmission of the transgene. To obtain Tg21;Chpi vac/vac mice, a three-generation breeding scheme was performed. Tg21;Chpi wild-type and PCR analysis for the BAC transgene were performed to obtain Tg21;Chpi B/C mice. Second, Tg21;Chpi B/C mice were crossed to Chpi vac/vac mice and Tg21;Chpi C/vac offspring were identified with three PCRs with the following primers: the Bac7TF and Bac237TR primers for the BAC transgene; the chmpmtF, chpmtF5, and chpmtF6 primer triplex for the Chpi vac allele; and the microsatellite marker D2MIT397, which cosegregates with the Chpi locus and is polymorphic between the C57BL/6J and C3H/HeJ strains, to distinguish the Chpi wild-type and Chpi vac alleles. Finally, Tg21;Chpi vac mice were crossed to Chpi vac/vac mice to produce Tg21;Chpi vac/vac mice.

Genomic mapping. Homozygous vac mice were crossed to BALB/cByJ mice and F1 heterozygotes were intercrossed to generate F2 mice. Genome scans were performed with polymorphic microsatellite markers using genomic DNA collected from 15 affected and 15 unaffected F2 mice. For fine mapping, F2 mice were analyzed using polymorphic microsatellite markers (MIT markers) and single nucleotide polymorphisms. To further narrow the critical interval, homozygous vac mice were also crossed with the C3H/HeJ and CAST/EiJ strains to generate F2 mice.

Plasmid construction. RT-PCR products for both wild-type and vac mutant Chpi were PCR amplified with chpBamHI: 5’-CAAGAGATTCCGGAGGAGCTGCCCCTGCAC-3’ and chpBfTAAR: 5’-ATGAGGATCCCGAATTCCTTGCAC-3’ primers. The resulting PCR products were inserted into the BamHI/EcoRV sites of the mammalian expression vector pCMV-3Tag (Agilent Technologies) in the appropriate reading frame so that the three FLAG epitope was included at the C terminus of each isoform for immunological detection.

RT-PCR. Total RNA was purified from wild-type or vac/vac cerebella using TRIzol Reagent (Invitrogen/Life Technologies). First-strand cDNA synthesis was performed with SuperScript III Reverse Transcriptase (Invitrogen/Life Technologies) according to the manufacturer’s instructions. Chpi full-length cDNAs were amplified with a forward primer chpex1F (5’-TCTTGCGCCGTCTGCTTCG-3’) which is located upstream of ATG start codon, and a reverse primer chpex5R (5’-CAAGGAACCTTGCCAAATG-3’) which is located downstream of the stop codon and recognizes the last eight nucleotides of the genomic sequence. GAPDH PCR was included as an internal control using GAPDH-5/F: 5’-GGAGAAGCTGCCCCAGATG-3’ and GAPDH-7/6R: 5’-CATTGTACACCCGAAATG-3’ primers.

Relative expression levels of mutant vs wild-type Chpi transcripts were analyzed using real-time, quantitative RT-PCR. All samples within an experiment were reverse transcribed and the resulting cDNAs were diluted 1:2 in nuclease-free water. Triplicate PCRs were performed for each primer pair. PCRs were performed using iQ SYBR green PCR master mix in an iQ5 iCycler thermal cycle (Bio-Rad). The thermal cycling conditions were 3 min at 95°C and then 40 cycles of 20 s at 95°C, 30 s at 59°C, and 20 s at 72°C. The relative quantitation in gene expression was calculated using the 2 ΔΔCT method (Livak and Schmittgen, 2001). GAPDH was used as an internal control. To detect all Chpi isoforms, primer pair chpex2F and chpex2R: 5’-ATCGACTGTGGGAAAAACCC-3’ were used. To detect the correctly spliced form, wild-type and Chpi transcripts, chpex5F: 5’-AGGAGGCTGACCAAGATGGTG-3’ and chpex6R: 5’-TCTGTGAAAGATGGCGCCAC-3’ were used.

Cell culture and DNA transfection. Chinese hamster ovary cells devoid of plasma membrane Na+/H+ exchange activity (AP-1 cells) (Rotin and Grinstein, 1989) were maintained in α-MEM containing 10% fetal bovine serum, 100 units/ml penicillin/streptomycin, and 25 mM NaHCO3, pH 7.4, at 37°C, 5% CO2. Transient transfections were performed with
Lipofectamine 2000 (Invitrogen/Life Technologies) according to the manufacturer’s protocol.

Western blotting. Tissues or cells were lysed in RIPA lysis buffer (25 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% sodium deoxycholate, 0.1% SDS, 1% NP-40, supplemented with complete protease inhibitor mixture [Roche]). Protein concentration was determined using the DC Protein Assay (Bio-Rad). Lysates were separated by SDS-PAGE gels and transferred to PVDF membranes (GE Healthcare) using standard techniques. Primary antibodies were detected with either an anti-mouse or anti-rabbit HRP-conjugated secondary antibody (1: 2000; Bio-Rad) and signal was developed using Supersignal West Pico Chemiluminescent Substrate (Pierce). Western blot bands were quantified by densitometry using the gel analysis tool of ImageJ software and normalized to GAPDH. Primary antibodies for Western blots were as follows: mouse anti-FLAG antibody (#F3165; Sigma), mouse anti-HA (Covance), rabbit anti-CHP1 (1:250), rabbit anti-CHP3 (Tescalcin) (1: 30; Proteintech), mouse anti-NHE1 (1:300), rabbit anti-NHE1 (1:400; #SAB4200016; Sigma), mouse anti-PMCA (1:500; Abcam), mouse anti-Syntaxin-1 (1:500; Sigma), rat anti-Hsp90 (1:200; Stressgen), and rabbit anti-GAPDH (1:2000; Cell Signaling Technology).

Coimmunoprecipitation. AP-1 cells were transiently transfected with individual variants of CHP13FLAG constructs. Cell lysates were collected 24h after transfection as described previously (Zaun et al., 2008). Lysates were centrifuged for 20 min at 4°C to pellet cellular debris and supernatants were precleared with 100 µl of 50% protein G-Sepharose slurry (GE Healthcare) in RIPA buffer for 2 h at 4°C. The protein G-Sepharose slurry was removed by brief centrifugation and a fraction of each lysate was removed for Western blotting. Rabbit polyclonal antibodies specific to the FLAG epitope were added to the remaining lysates and incubated with gentle rocking overnight at 4°C. Next, 100 µl of the 50% protein G-Sepharose slurry was added to each tube and incubated for several hours at 4°C with gentle rocking, followed by 6 washes in RIPA buffer. Protein conjugates were eluted by SDS sample buffer and incubated for 30 min at room temperature without boiling to minimize aggregation of the NHE1 proteins. Samples were then subjected to SDS-PAGE and Western blotting.

In vivo coimmunoprecipitation was performed with mouse cerebellar lysate prepared by homogenization in tenfold ice-cold immunoprecipitation buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 1% Triton X-100) supplemented with protease inhibitors. Homogenates were incubated at 4°C for 1 h with gentle agitation, centrifuged at 1000 × g for 10 min to pellet nuclei and cellular debris, and then precleared with Dynabeads protein G (Invitrogen/Life Technologies) for 30 min at 4°C. After removal of beads, a fraction of each lysate was used for Western blotting. The remaining lysates were added to antibody-protein G complexes that were preformed by incubation of beads with either mouse monoclonal antibody to NHE1, rabbit polyclonal antibodies to CHPI, or for controls, normal mouse or rabbit IgG (Santa Cruz Biotechnology) at 4°C for 1.5 h. Immunoprecipitation was performed overnight at 4°C and protein conjugates were eluted with 4 × lithium dodecyl sulfate sample buffer (Pierce) at 50°C. Samples were analyzed with SDS-PAGE and Western blotting.

Membrane fractionation. Mouse cerebella were homogenized in a 10-fold ice-cold buffer (0.32 M sucrose, 10 mM HEPES-Na, pH 7.4, and protease inhibitors) using 15 strokes of a glass Teflon homogenizer. The homogenate was centrifuged at 1000 × g for 5 min at 4°C to remove the pelletted nuclear fraction (P1). The remaining supernatant (S1) was spun at 20,800 × g for 30 min at 4°C to yield the soluble cytoplasmic (S2) and membrane (P2) fractions. The P2 pellet was dissolved in RIPA buffer containing 2% lithium dodecyl sulfate. Equal amounts of protein from each fraction were then subjected to SDS-PAGE and Western blotting analysis.

Statistical analysis. All data are presented as means ± SEM. The difference between two groups was assessed by Student’s t test; p < 0.05 was considered statistically significant. GraphPad Prism version 6 software was used for two-way ANOVA analysis.

Results

vac mutation causes ataxia and axonal degeneration of cerebellar Purkinje cells

The vac mutation was identified in an ENU-induced mutagenesis screen for recessive mutations. Mice homozygous for this mutation appeared indistinguishable from their wild-type or heterozygous littermates before 4 weeks of age. However, at 4–5 weeks of age, homozygous mutant mice displayed mild tremors and an ataxic gait that became pronounced by 7 weeks of age. Concomitant with the onset of locomotor abnormalities, vac/vac mice developed extensive axonal dystrophy of cerebellar Purkinje cells, the projections of which constitute the sole output of the cerebellar cortex.

Immunohistochemistry of brain sections from 5-week-old mutant mice using antibodies to the Purkinje cell markers calbindin-D28 or PKCγ (Barmack et al., 2000) revealed widespread hypertrophy of Purkinje cell axons (Fig. 1A and data not shown). These axons also had many abnormal focal swellings forming varicosities or large spheroids, characteristic hallmarks of degenerating axons (Dusart and Sotelo, 1994). In contrast, axons in the wild-type cerebellum were thin and of uniform caliber (Fig. 1B).

Previous studies have shown that accumulation of neurofilaments is often observed in injured or diseased axons (Petzold, 2005). Indeed, immunofluorescence with an antibody to neurofilament medium chain (NFM) revealed increased staining in both hypertrophic axons and axonal torpedoes in the vac/vac cerebellum, but not in other brain regions (Fig. 1C–H and data not shown). Coimmunofluorescence with antibodies to NFM and calbindin D-28 revealed that axons with increased levels of NFM were also reactive with anti-calbindin D-28 antibodies, demonstrating that axons of Purkinje cells were selectively affected by the vac mutation.

To further illustrate the degeneration of Purkinje cell axons, cerebellar white matter tracts of the vac mutant and wild-type mice were examined by transmission electron microscopy. Electron micrographs showed that axonopathies, including myelin sheath decompaction and detachment, accumulation of organelles in swollen nerve fibers, and the presence of vacant areas due to degeneration of nerve fibers, were widespread within the white matter of the vac mutant cerebellum, but were completely absent from the same region in the wild-type cerebellum, confirming our immunofluorescence results (Fig. 1I, J and data not shown).

The effect of the vac mutation on Purkinje cell survival in aged mice was investigated by calbindin D-28 immunohistochemistry and hematoxylin and eosin staining of cerebella from 7-week-old, 4-month-old, and 10-month-old vac/vac mice (Fig. 2 and data not shown). Despite extensive degeneration of Purkinje cell axons, no loss of these neurons was observed at 7 weeks of age. However, at 4 months of age, Purkinje cell death was apparent in the mutant, but not the heterozygous or wild-type cerebellum.

The degeneration of Purkinje neurons was progressive, and by 10 months of age, homozygous mutant mice displayed mild tremors and an ataxic gait that became pronounced by 7 weeks of age. Concomitant with the onset of locomotor abnormalities, vac/vac mice developed extensive axonal dystrophy of cerebellar Purkinje cells, the projections of which constitute the sole output of the cerebellar cortex.

Early-onset degeneration of mutant Purkinje cell axon collaterals

To determine the onset of Purkinje cell axonal degeneration, immunofluorescence was performed with antibodies to PKCγ on wild-type and vac/vac cerebellar sections taken at daily intervals from postnatal day 8 (P8)–P20. Beginning at P15, abnormally enlarged spheroids with increased PKCγ expression were sporadically observed beneath the Purkinje cell layer and within the
lower molecular layer. These abnormal structures became more pronounced and widespread by P17 (Fig. 3 and data not shown).

The position of these PKCγ-positive spheroids suggests they are likely axonal boutons formed by Purkinje cell axon collaterals, which sprout from the axon shafts of Purkinje cells and synapse onto other Purkinje cells (Larramendi and Lemkey-Johnston, 1970). To further investigate the nature of the spheroids, co-immunofluorescence was performed with PKCγ antibodies to label structures of Purkinje cells and a GAD antibody to visualize GABAergic axon terminals. Indeed, the PKCγ-positive spheroids in the mutant cerebellum were also positive for GAD. Furthermore, in contrast to wild-type boutons that were closely juxtaposed to Purkinje cell dendrites, these misshapen boutons were often displaced. These observations demonstrated that degeneration of axon collaterals of vac/vac Purkinje cells was an early event in the cerebellar pathogenesis of this mutant strain.

vac mutation disrupts the mouse Chp1 gene

The vac mutation was initially mapped to chromosome 2 by a genome-wide scan of polymorphic markers on affected F2 mice. Analysis of additional F2 mice further narrowed the critical region to a 0.15 centimorgan interval (1.14 megabases) containing 31 protein-coding genes (Fig. 4A). We performed RT-PCR analysis of genes within the vac interval using cerebellar cDNAs and discovered aberrant Chp1 (also known as calcineurin B homologous protein 1 or 150003O03Rik) transcripts in the vac mutant, but not the wild-type cerebellum. Comparison of vac mutant and wild-type genomic DNA revealed an A to G base transition in exon 6 at nucleotide 657 of the Chp1 gene. As a result, an aspartic acid was changed to glycine at codon 168, which is the z position of the fourth EF hand (EF4) and one of the six residues that are involved in calcium ion binding (Barroso et al., 1996). Furthermore, analysis of mutant Chp1 RT-PCR products demonstrated that the A657G mutation created a novel splice donor site. This site, and cryptic splice sites in intron 6, caused the production of two aberrant transcripts: a shorter isoform containing a truncated exon 6 (dltCS) and a longer isoform (dltCL) consisting of the truncated exon 6 and an additional downstream exon. In both the dltCS and dltCL transcripts, a frameshift
occurred after the A657G mutation that caused deletion of the second half of EF4 (Fig. 4B, C). Quantitative real-time RT-PCR revealed that the overall expression of all three Chp1 transcripts in the mutant cerebellum was comparable to that of the wild-type transcript, with the correctly spliced missense transcript D168G constituting ~30% of all mutant Chp1 mRNAs (data not shown).

To determine whether the vac mutation affects CHPI protein levels, rabbit polyclonal antibodies were generated with recombinant full-length mouse CHPI protein as immunogen. These antibodies detected a single 22 kDa band in Western blots of cerebellar lysates prepared from P7 and 3-month-old wild-type mice. However, in CHPI vac/vac cerebellar samples, the antibodies recognized two closely migrating bands (Fig. 4D). Based on molecular mass prediction, the fainter, higher molecular weight band likely corresponded to the translation product of the dltCL transcript, whereas the protein products of the dltCS and D168G transcripts likely comigrated in the lower molecular weight band. Interestingly, although the levels of Chp1 mRNAs were not altered in the CHPI vac/vac cerebellum, we observed a 70% reduction of the total levels of CHPI protein isoforms in both the developing and the adult CHPI vac/vac cerebellum, suggesting that the mutant isoforms have reduced stability compared with the wild-type protein (Fig. 4E).

To confirm that the Chp1 vac mutant phenotype is indeed caused by mutation of the Chp1 gene, we performed an in vivo complementation assay. Transgenic mice were generated by pronuclear injection of a 200 kb wild-type BAC (RP23–222L23) containing the Chp1 gene. In addition, this BAC also covers three other genes, but no polymorphisms were detected in their coding sequences nor were their expression levels altered in the Chp1 vac/vac cerebellum (Fig. 4F and data not shown). Transgenic mice were bred with mice carrying the Chp1 vac mutation and their offspring were intercrossed to generate homozygous mutant mice with the BAC transgene (Tg21;Chp1 vac/vac). Immunohistochemistry with calbindin D-28 on cerebellar sections from 2- and 7-month-old Tg21;Chp1 vac/vac mice failed to reveal axonal defects or soma loss in these mice (Fig. 4G–J). Moreover, Tg21;Chp1 vac/vac mice displayed normal locomotor behavior that was indistinguishable from wild-type mice even after 1 year of age, suggesting that transgenic expression of Chp1 was sufficient to rescue cerebellar defects in Chp1 vac/vac mice (data not shown). This result also suggests that the mutant CHPI protein isoforms were not detrimental to neurons, consistent with the recessive inheritance of this mutation.

Mutation in Nhe1 leads to Purkinje cell axonal degeneration

CHPI has been shown to interact with and regulate members of the plasma membrane-localized NHES in vitro and in cell-based assays (Di Sole et al., 2012). Interestingly, ataxia and selective
death of neurons were reported in both a spontaneously occurring mouse mutant allele (Nhe1<sup>swe</sup>) and in a targeted allele of Nhe1, which is the most widely expressed NHE family member (Cox et al., 1997; Bell et al., 1999). These findings prompted us to hypothesize that disruption of this exchanger could underlie the phenotypes observed in the Nhe1<sup>swe/swe</sup> mouse.

To determine whether axon degeneration of Purkinje cells also occurs in Nhe1-deficient mice, we performed calbindin D-28 immunohistochemistry on cerebellar sections from P21 Nhe1<sup>swe/swe</sup> and wild-type mice. Similar to Chp1<sup>vac/vac</sup> mice, Purkinje cell axons in the Nhe1<sup>mutant</sup> cerebellum were hypertrophic with increased expression of NFM compared with wild-type axons (Fig. 5A–F). Because degeneration of Purkinje cell axon collaterals was among the earliest pathological features in the Chp1<sup>vac/vac</sup> cerebellum, we assessed local PKCγ expression in Purkinje cell axons by immunofluorescence on cerebellar sections from P8 to P21 Nhe1<sup>swe/swe</sup> mice. Indeed, swollen and displaced collateral boutons were identified as early as P14 in the Nhe1<sup>swe/swe</sup> cerebellum and these abnormalities became more pronounced with age (Fig. 5G–I and data not shown).

To determine whether ablation of Nhe1, like mutation of Chp1, causes loss of Purkinje cells in aged mice, cerebella from 4-month-old Nhe1<sup>swe/swe</sup> mice were analyzed by calbindin-D28 immunohistochemistry. By this age, most Purkinje cell axons had degenerated in these mice, as shown by the near complete absence of calbindin-positive Purkinje cell axon tracts within the white matter and the presence of many hypertrophic axon fragments in the granule cell layer (Fig. 5J–L). Surprisingly, in contrast to Chp1<sup>vac/vac</sup> mutant mice, no loss of Purkinje cells was observed in the Nhe1<sup>swe/swe</sup> cerebellum. These results indicate that axon degeneration and cell death of Purkinje cells are likely two discrete processes and that NHE1 function is critical for the former, but not the latter, event.

**CHP1 is required for biosynthetic maturation of NHE1**

NHE1 is a principle plasma membrane target for CHP1 (Lin and Barber, 1996; Pang et al., 2001). The striking similarity of Purkinje cell axonal defects in Chp1<sup>vac/vac</sup> and Nhe1<sup>swe/swe</sup> mice suggests that the axonal abnormalities observed in the Chp1 mutant cerebellum are mediated by disruption of NHE1 activity. CHP1 binds the juxtamembrane region of NHE1 via a hydrophobic pocket opposite the EF hands (Mishima et al., 2007). Upon NHE1 binding, the Ca<sup>2+</sup> affinity of the two functional EF-hand domains (EF3 and EF4) in CHP1 increases. Disruption of either
Figure 5. NHE1 deficiency causes degeneration of Purkinje cell axons without loss of cell bodies. A–C, Hypertrophic axons (arrowheads) in the 7-week-old Nhe1<sup>swe/swe</sup> (swe/swe) cerebellum. These axons display intraaxonal accumulation of the neurofilament subunit NFM (A) and are reactive with calbindin D-28 antibodies (B; merge in C). Representative Purkinje cell axons in the wild-type (WT) cerebellum are indicated by arrowheads in D–F. G–I, Degeneration of Purkinje cell axon collaterals in Nhe1<sup>swe/swe</sup> cerebellum occurred from P14 as shown by PKCγ immunostaining. Note the swollen collateral boutons (G, arrows) and misplaced collateral projections (H, arrows) observed in Nhe1<sup>swe/swe</sup> but not the WT cerebellum (I). Arrows in I indicate representative WT collateral boutons. J–L, Sagittal sections of 4-month-old Nhe1<sup>swe/swe</sup> (J, K) and wild-type (L) cerebella were immunostained with calbindin-D28 antibodies (brown). J, Lower-magnification image showing the absence of Purkinje cell death in the Nhe1<sup>swe/swe</sup> cerebellum. K, Higher-magnification image showing extensive Purkinje cell axon degeneration, indicated by the absence of calbindin D28 positivity in the white matter of Nhe1<sup>swe/swe</sup> cerebellar folia (region demarcated by red dashed lines) and the numerous severed Purkinje cell axons with characteristic bulbous ends (arrowheads) in the granule layer. L, Purkinje cell axons in the WT cerebellum are slender and plenty (arrowheads and region demarcated by red dashed lines). Sections were counterstained by hematoxylin. Scale bars: A–F, 40 μm; G–I, 30 μm; J, 800 μm; K, L, 80 μm.
To determine whether CHPI and NHE1 interact in vivo, we performed coinmunoprecipitation assays using cerebellar extracts from P7 and 3-month-old wild-type mice. Indeed, NHE1, the majority of which is fully glycosylated in the cerebellum, was immunoprecipitated with CHPI antibodies, confirming that CHPI is complexed with NHE1 in the developing and adult cerebellum (Fig. 6B). In addition, NHE1 was also immunoprecipitated from CHPIvac/vac cerebellum by CHPI antibodies, although at reduced levels. This reduction in immunoprecipitated NHE1 may be indicative of a reduced affinity of mutant CHPI for NHE1 in vivo or it may simply reflect the reduced levels of mutant CHPI isoforms in the CHPIvac/vac cerebellum.

Recent studies have indicated that CHPI and other CHF family members promote the oligosaccharide maturation and trafficking of NHE1 from the endoplasmic reticulum to the plasma membrane as well as its stability (Zaun et al., 2008; Matsushita et al., 2011). Because the bulk of fully glycosylated NHE1 resides at the plasma membrane whereas the core-glycosylated species remains intracellular (Aharonovitz et al., 2000; Zaun et al., 2008), the glycosylation status of the exchanger can be used as a convenient indicator of its posttranslational processing and trafficking to the cell surface.

To determine whether the CHPI mutant isoforms affect the biosynthetic processing of NHE1, AP-1 cells were transiently cotransfected with constructs encoding HA-tagged NHE1 and FLAG-tagged wild-type or mutant forms of CHPI. Cell lysates were collected at various time points after transfection and Western blot analysis was performed to detect the expression of NHE1. As shown in Figure 7, A and B, coexpression of wild-type CHPI led to a significant increase in the ratio of fully glycosylated to core-glycosylated NHE1 compared with control cells that were only cotransfected with empty vector (p < 0.05). A similar increase was observed when cells were cotransfected with a construct encoding the CHPID168G isoform. However, expression of the EP4-truncated CHPIDLC isoform failed to alter the ratio of mature versus immature NHE1 forms, suggesting that this form of CHPI is defective in promoting the synthesis of the fully glycosylated exchanger. Similar results were obtained in transfected HEK293T cells (data not shown).

To determine whether NHE1 maturation is disrupted by the CHPI mutation in vivo, we examined NHE1 levels in the wild-type and CHPIvac/vac cerebellum. Given the early onset of Purkinje axon defects in both the Nhe1swe/swe and CHPIvac/vac mutants, cerebellar extracts were generated from mice at 1, 2, and 3 weeks of age. In the 1-week-old CHPIvac/vac mouse cerebellum, the NHE1 level was reduced to 20% of the wild-type, consistent with our in vitro finding that mutant CHPI is less efficient in promoting the maturation of NHE1 (Fig. 7C,D).

Surprisingly, levels of NHE1 greatly increased during postnatal development of the CHPIvac/vac cerebellum. In the cerebella of 2- and 3-week-old mutant mice, NHE1 was 75% and 71% of wild-type levels, respectively, indicating that a protein other than CHPI promotes NHE1 maturation during later cerebellar development. CHP3 has been detected in the adult brain, whereas CHP2 was only detected in the intestine and a few cancer cell lines (Pang et al., 2002; Gutierrez-Ford et al., 2003; Inoue et al., 2003).

Therefore, we examined CHP3 levels at various time points in the postnatal cerebellum. Western blot analysis demonstrated that, unlike CHPI, the levels of CHP3 were low at 1 week, but dramatically increased at 2 and 3 weeks, suggesting that CHP3 compensates for the loss of CHPI during late postnatal cerebellar development.
Membrane expression of CHP1 is dependent on NHE1

To determine how disruption of NHE1/CHP1 affects Purkinje cell axon survival, we investigated the localization of CHP1 and NHE1 in the cerebellum by immunofluorescence. In the wild-type cerebellum at P8, just before the occurrence of the axonal defects in the Chp1 vac/vac cerebellum, strong CHP1-positive puncta were observed in the deep white matter surrounding the deep cerebellar nuclei (DCN). These puncta were reminiscent of Purkinje cell axon terminals that form GABAergic synapses with the DCN (Fig. 8A). The expression of CHP1 at Purkinje cell presynaptic terminals was confirmed by the overlapping immunostaining pattern of CHP1 and calbindin D-28 (Fig. 8B, C). The specificity of the CHP1 antibodies for immunohistochemistry was confirmed by immunostaining of Chp1 vac/vac cerebella, in which no signal was detected, which was consistent with earlier Western blot results (data not shown).

To determine whether NHE1 is required for presynaptic localization of CHP1, we performed immunostaining of CHP1 in the Nhe1 swe/swe cerebellum. In the absence of NHE1, CHP1 expression was significantly reduced in Purkinje cell axon terminals within the deep white matter (Fig. 8D–F). Similar results were obtained by coimmunofluorescence of CHP1 and GAD in the cerebellar DCN region (data not shown). In addition to expression in the Purkinje cell axon terminals, CHP1 was expressed prominently in the cytoplasm of both Purkinje cells and DCN neurons (Fig. 8A, G). Interestingly, the cytoplasmic expression of CHP1 in mutant Purkinje cells and DCN neurons was not obviously altered, suggesting that depletion of NHE1 specifically affects the presynaptic, but not the intracellular, localization of CHP1 (Fig. 8D, F).

CHP1 localization to axon terminals was not limited to Purkinje cells, but was also observed in a wide variety of other neurons in the brain throughout development, as exemplified by the localization of CHP1 in the pinceau synapses of basket cell axons and mossy fibers and their terminals in the inner granule cell layer of the adult wild-type cerebellum (Fig. 8M–O and data not shown). Similarly, depletion of NHE1 greatly decreased the axonal localization of CHP1 in these regions (Fig. 8P–R), suggesting that NHE1 serves as a membrane anchor for enrichment of CHP1 at several presynaptic terminals of axons in the brain.

The requirement of NHE1 for plasma membrane localization of CHP1 was further confirmed by the loss of CHP1 expression in the cerebellum of NHE1 null mice. In the absence of NHE1, CHP1 expression was significantly reduced in Purkinje cell axon terminals within the deep white matter (Fig. 8D–F). Similar results were obtained by coimmunofluorescence of CHP1 and GAD in the cerebellar DCN region (data not shown). In addition to expression in the Purkinje cell axon terminals, CHP1 was expressed prominently in the cytoplasm of both Purkinje cells and DCN neurons (Fig. 8A, G). Interestingly, the cytoplasmic expression of CHP1 in mutant Purkinje cells and DCN neurons was not obviously altered, suggesting that depletion of NHE1 specifically affects the presynaptic, but not the intracellular, localization of CHP1 (Fig. 8D, F).

CHP1 localization to axon terminals was not limited to Purkinje cells, but was also observed in a wide variety of other neurons in the brain throughout development, as exemplified by the localization of CHP1 in the pinceau synapses of basket cell axons and mossy fibers and their terminals in the inner granule cell layer of the adult wild-type cerebellum (Fig. 8M–O and data not shown). Similarly, depletion of NHE1 greatly decreased the axonal localization of CHP1 in these regions (Fig. 8P–R), suggesting that NHE1 serves as a membrane anchor for enrichment of CHP1 at several presynaptic terminals of axons in the brain.

The requirement of NHE1 for plasma membrane localization of CHP1 was further confirmed by the loss of CHP1 expression in the cerebellum of NHE1 null mice. In the absence of NHE1, CHP1 expression was significantly reduced in Purkinje cell axon terminals within the deep white matter (Fig. 8D–F). Similar results were obtained by coimmunofluorescence of CHP1 and GAD in the cerebellar DCN region (data not shown). In addition to expression in the Purkinje cell axon terminals, CHP1 was expressed prominently in the cytoplasm of both Purkinje cells and DCN neurons (Fig. 8A, G). Interestingly, the cytoplasmic expression of CHP1 in mutant Purkinje cells and DCN neurons was not obviously altered, suggesting that depletion of NHE1 specifically affects the presynaptic, but not the intracellular, localization of CHP1 (Fig. 8D, F).

CHP1 localization to axon terminals was not limited to Purkinje cells, but was also observed in a wide variety of other neurons in the brain throughout development, as exemplified by the localization of CHP1 in the pinceau synapses of basket cell axons and mossy fibers and their terminals in the inner granule cell layer of the adult wild-type cerebellum (Fig. 8M–O and data not shown). Similarly, depletion of NHE1 greatly decreased the axonal localization of CHP1 in these regions (Fig. 8P–R), suggesting that NHE1 serves as a membrane anchor for enrichment of CHP1 at several presynaptic terminals of axons in the brain.

The requirement of NHE1 for plasma membrane localization of CHP1 was further confirmed by the loss of CHP1 expression in the cerebellum of NHE1 null mice. In the absence of NHE1, CHP1 expression was significantly reduced in Purkinje cell axon terminals within the deep white matter (Fig. 8D–F). Similar results were obtained by coimmunofluorescence of CHP1 and GAD in the cerebellar DCN region (data not shown). In addition to expression in the Purkinje cell axon terminals, CHP1 was expressed prominently in the cytoplasm of both Purkinje cells and DCN neurons (Fig. 8A, G). Interestingly, the cytoplasmic expression of CHP1 in mutant Purkinje cells and DCN neurons was not obviously altered, suggesting that depletion of NHE1 specifically affects the presynaptic, but not the intracellular, localization of CHP1 (Fig. 8D, F).

CHP1 localization to axon terminals was not limited to Purkinje cells, but was also observed in a wide variety of other neurons in the brain throughout development, as exemplified by the localization of CHP1 in the pinceau synapses of basket cell axons and mossy fibers and their terminals in the inner granule cell layer of the adult wild-type cerebellum (Fig. 8M–O and data not shown). Similarly, depletion of NHE1 greatly decreased the axonal localization of CHP1 in these regions (Fig. 8P–R), suggesting that NHE1 serves as a membrane anchor for enrichment of CHP1 at several presynaptic terminals of axons in the brain.

The requirement of NHE1 for plasma membrane localization of CHP1 was further confirmed by the loss of CHP1 expression in the cerebellum of NHE1 null mice. In the absence of NHE1, CHP1 expression was significantly reduced in Purkinje cell axon terminals within the deep white matter (Fig. 8D–F). Similar results were obtained by coimmunofluorescence of CHP1 and GAD in the cerebellar DCN region (data not shown). In addition to expression in the Purkinje cell axon terminals, CHP1 was expressed prominently in the cytoplasm of both Purkinje cells and DCN neurons (Fig. 8A, G). Interestingly, the cytoplasmic expression of CHP1 in mutant Purkinje cells and DCN neurons was not obviously altered, suggesting that depletion of NHE1 specifically affects the presynaptic, but not the intracellular, localization of CHP1 (Fig. 8D, F).
ther examined by subcellular fractionation and Western blot analysis. P8 wild-type, Nhe1swe/swe, and Chp1vak/vac cerebellar lysates were separated into cytoplasmic and crude synaptosomal membrane fractions by differential centrifugation. The efficiency of the separation was demonstrated by the relative enrichment of the PCMA (plasma membrane), syntaxin-1 (presynaptic membrane), and Hsp90 (cytosolic) proteins (Fig. 9). These results demonstrated that NHE1 was abundant in the membrane, but not the cytoplasmic fraction.

Figure 8. The localization of CHP1 at axon terminals is dependent on NHE1. Representative images of sagittal sections of P8 wild-type (WT; A–C, G–I) and Nhe1swe/swe (swe/swe; D–F, J–L) cerebella were immunostained with antibodies to CHP1 (A, D, G, J) and calbindin D-28 (to label Purkinje cells and their axon terminals that synapse onto the DCN neurons in the deep cerebellar white matter, as visualized by the punctate staining surrounding the DCN neurons; B, E, H, K). Merged images are shown in C, F, I, L, A–C. Note the strong CHP1 immunoreactivity in the cell body and processes of the DCN neurons, as well as the punctate CHP1 staining surrounding the DCNs that overlaps with calbindin signals in the WT cerebellum. D–F, In the Nhe1swe/swe cerebellum, CHP1-positive signals were greatly decreased in areas surrounding the DCN neurons, but still present in the DCN soma and processes. G–L, Purkinje cells in the cerebellar cortex are positive for CHP1 both in the WT (G–I) and swe/swe mouse (J–L). M–R, Double immunofluorescence staining with antibodies to CHP1 (J, M) and GAD (K, N) and merged images (L, O) in 2-month-old WT (J–L) and Nhe1swe/swe (M–O) cerebellar sections. Arrows point to the pinceau synapses that were recognized by their GAD positivity, their distinctive pinceau (paintbrush) shape, and their location around the Purkinje (Pkj) axon hillock. Mol, molecular layer; PCL, Purkinje cell layer; IGL, inner granule cell layer. Camera exposure times were equal for images of the same channel. Scale bars: A–F, 25 μm; G–R, 20 μm.
The expression of NHE1 was greatly reduced in the Chp1 vac/vac cerebellum. Conversely, CHP1 was present in both the membrane and cytosolic fractions, with ~88% and ~12% of total CHP1 in these fractions, respectively. In the Nhe1 swe/swe cerebellum, CHP1 was decreased in both its overall level and in the membrane fraction compared with the wild-type cerebellum. However, no change was observed in the cytosolic levels of CHP1 between the Nhe1 swe/swe and wild-type cerebellum, suggesting that the membrane, but not the cytoplasmic, localization of CHP1 is largely dependent on NHE1 in vivo.

CHP1 is required for NHE1 localization at a subset of presynaptic terminals

To further illustrate the nature of CHP1 and NHE1 interactions, we investigated the effect of the Chp1 vac mutation on the subcellular distribution of NHE1 in the mouse cerebellum. Similar to CHP1, strong NHE1 immunoreactivity was detected in Purkinje cell axon terminals in the P8 wild-type cerebellum, as indicated by the punctate staining of NHE1 that overlapped with that of calbindin D-28 in the deep white matter (Fig. 10A–C). Co-immunofluorescence using antibodies to NHE1 and CHP1 also demonstrated significant overlap of signals (data not shown). The expression of NHE1 was greatly reduced in the deep white matter of the P8 Chp1 vac/vac cerebellum, indicating that the Chp1 vac mutation disrupts the presynaptic localization of NHE1 in Purkinje cell axons (Fig. 10D–F). The specificity of the NHE1 antibody was confirmed by the absence of NHE1-positive signal in Nhe1 swe/swe brain sections (Fig. 10G–I).

The effect of the Chp1 vac mutation on the membrane distribution of NHE1 was further explored by comparison of the NHE1 immunostaining pattern in adult wild-type and Chp1 vac/vac cerebella. In the cerebella of 2-month-old wild-type mice, NHE1 expression was detected in multiple axonal structures, including the pinceau synapses, mossy fibers and their terminals, and parallel fibers (Fig. 10J–L). In the Chp1 vac/vac cerebellum, NHE1 was not detectable in pinceau synapses, but was still present in mossy fibers and parallel fibers (Fig. 10M–O). These data suggest that disruption of CHP1 specifically affects membrane expression of NHE1 in a subset of neurons, mostly likely through decreasing the synthesis of the fully glycosylated form of the protein.

Discussion

Axon degeneration is an early and potentially causal event in a variety of human neurodegenerative disorders. However, the molecular mechanisms that initiate the degenerative process of axons are largely unknown. Here, we identified a novel ataxic mouse mutant, vaciller, which displays extensive degeneration of cerebellar Purkinje cell axons. By positional cloning, we identified the vaciller mutation in the Chp1 gene, which encodes an EF-hand Ca2+–binding protein, a positive regulator of sodium hydrogen exchangers. We further showed that mutation of Chp1 affected the synthesis of fully glycosylated NHE1 and cell surface expression of this protein. Therefore, NHE1 localization at the axon terminals of Purkinje cells was severely decreased in the Chp1 vac/vac cerebellum. In fact, upon examination of Nhe1-deficient mice, we discovered that Purkinje cell axons degenerate in these mice, confirming the importance of NHE1 for axon homeostasis.

The relationship of axon degeneration and neuronal loss has been debated due to the intricacy of many neurodegenerative disorders (Medana and Esiri, 2003; Coleman, 2005; Saxena and Caroni, 2007). Here we provide further evidence to support the idea that, at least in a subset of neurodegenerative disorders, disturbances of discrete cellular pathways may underlie axon degeneration and cell death. Axonal degeneration occurs in the postnatal cerebellum of Chp1 vac/vac mice, with neuronal loss occurring much later. In contrast, Nhe1 swe/swe mice have early Purkinje axonal loss without cell body degeneration. Therefore, it is apparent that axon degeneration of Purkinje cells can be separable from death of these neurons, a finding consistent with a previous observation that acute axotomy in the adult rat cerebellum did not induce Purkinje cell loss (Dusart and Sotelo, 1994). The mechanisms for the late-onset death of Chp1-deficient Purkinje cells remain unclear. In addition to NHE1, CHP1 complexes with other NHEs, regulating their plasma membrane localization (Pang et al., 2001; Di Sole et al., 2009; Y.L. and S.L.A., unpublished observations). In the Purkinje cells of the adult rat cerebellum, transcripts of NHE2–4 are also present and likely participate in regulating the intracellular pH of the Purkinje cell soma (Ma and Haddad, 1997; Lein et al., 2007). Therefore, deficiency of CHP1 may cause Purkinje cell loss by compromising the activities of all NHE isoforms in the adult Purkinje cell.

CHP1 consists of four EF hands; however, only EF3 and EF4 are capable of binding calcium ions (Lin and Barber, 1996). All three CHP1 mutant isoforms harbor an amino acid substitution at the z position of EF4, one of the six EF-hand amino acid residues that are involved in the Ca2+ binding. The Chp1 vac mutation also causes abnormal splicing that leads to trunc-
tion of the second half of EF4 in two mutant isoforms (dltCS and dltCL). Unlike the D168G isoform, the dltC isoforms completely lack the ability to promote the full glycosylation and membrane expression of NHE1. Furthermore, although the total level of mutant transcripts was unchanged, all three mutant proteins displayed reduced protein levels in the cerebellum, suggesting that even though the D168G CHP1 isoform is competent to promote NHE1 maturation, it has reduced stability. These data suggest that the vac mutation is a severe hypomorphic, rather than a null, allele of Chp1. We suspect that complete loss of CHP1 may cause more severe or broader defects than this allele.
Our observations that NHE1 levels were not changed in many axonal tracts and terminals in the Chp1<sup>+/+</sup>/vac brain, particularly in the adult, suggests that other CHP proteins may compensate for the loss of CHP1 in these neurons. In agreement, in situ analysis (www.brain-map.org) showed that both Chp1 and Chp3 transcripts were expressed in cerebellar granule cells, whereas only Chp1 was expressed in Purkinje cells (Lein et al., 2007). Moreover, we found temporal differences in the protein levels of Chp3 and Chp1 in the mouse cerebellum. Although CHP1 levels remained constant from the early postnatal to the adult cerebellum, CHP3 levels were very low at P7 but steadily increased during the course of cerebellar development. Therefore, CHP1 is likely necessary for the cell surface expression of NHEs during early postnatal development, whereas CHP3 may compensate for the loss of CHP1 in a subset of neurons in the adult brain. This compensation may explain the absence of some of the non-Purkinje cell phenotypes in Chp1-deficient mice (e.g., DCN degeneration and seizures) that were observed in Nhe1<sup>+/+</sup>/vac mice (Cox et al., 1997). Alternatively, phenotypic differences between these mutant strains could be due to low levels of the CHP1<sup>+/+</sup> isoform that may promote maturation of a limited amount of NHE1, which, in some neurons, could be sufficient for their survival and/or function.

Although we have shown here that disruption of NHE1 function causes Purkinje cell axon degeneration, the mechanism by which NHE1 causing axonal defects remains unclear. Recent in vitro studies have implicated an important role for NHE1 in early neurite morphogenesis of PC12 neuroendocrine cells and murine neocortical neurons (Sin et al., 2009). Similarly, NHE5 has been shown to be actively recruited to dendritic spines and to be involved in local pH regulation that affects spine growth (Diering et al., 2011). Other studies suggest that NHE1 function and pH regulation are important in the modulation of synaptic activity, which in turn may affect axon homeostasis (Dietrich and Morad, 2010). In addition to synaptic dysfunction, NHE1 deficiency may cause misregulation of other ions such as calcium due to the functional coupling of ion pumps and exchangers at the synapse. Indeed, it has been shown that the perturbations in intracellular calcium and sodium homeostasis via functional coupling of NHE1 and NCX1 play key roles in ischemic cell death of the heart (Hilgemann et al., 2006). Not surprisingly, we observed localization of NCX1 at presynaptic terminals of Purkinje cells in the P8 wild-type cerebellum, suggesting that active regulation of Ca<sup>2+</sup> homeostasis occurs during the maturation of the presynaptic terminals of Purkinje cells (Y.L. and S.L.A., unpublished observations). Although more research is needed to elucidate the mechanisms by which NHE1 deficiency initiates axon degeneration, our results demonstrate the importance of this exchanger for axon integrity.

References

tional significance of calcineurin homologous protein 1 binding to Na(+)/H(+) exchanger isoform 1. Am J Physiol Cell Physiol 301: C280–C288. CrossRef Medline


